Supernus Pharmaceuticals (NASDAQ:SUPN) Posts Quarterly Earnings Results, Misses Estimates By $0.03 EPS

Posted by William Tyler on Aug 7th, 2024

Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) released its quarterly earnings results on Tuesday. The specialty pharmaceutical company reported $0.36 earnings per share for the quarter, missing the consensus estimate of $0.39 by ($0.03), Briefing.com reports. Supernus Pharmaceuticals had a negative net margin of 2.60% and a negative return on equity of 1.68%. The company had revenue of $168.30 million during the quarter, compared to analyst estimates of $148.83 million. During the same quarter last year, the company earned ($0.02) EPS. The firm’s quarterly revenue was up 24.1% compared to the same quarter last year. Supernus Pharmaceuticals updated its FY 2024 guidance to EPS.

Supernus Pharmaceuticals Stock Performance

NASDAQ:SUPN traded up $4.25 during mid-day trading on Wednesday, reaching $32.13. 1,187,476 shares of the company’s stock were exchanged, compared to its average volume of 478,993. Supernus Pharmaceuticals has a one year low of $21.99 and a one year high of $35.44. The firm has a market capitalization of $1.77 billion, a PE ratio of -113.62 and a beta of 0.90. The business’s fifty day simple moving average is $27.72 and its two-hundred day simple moving average is $29.34.

Insider Activity

In other news, insider Tillotson Martin Tami 2,900 shares of the company’s stock in a transaction that occurred on Tuesday, July 30th. The was disclosed in a legal filing with the SEC, which is available at this hyperlink. 8.76% of the stock is currently owned by corporate insiders.

About Supernus Pharmaceuticals

(Get Free Report)

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.